MEREO BIOPHARMA GROUP PLC Deferred Tax Assets, in Process Research and Development
MEREO BIOPHARMA GROUP PLC (MREO) had Deferred Tax Assets, in Process Research and Development of $78.34 million as of 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2026-03-19
- 2025-12-31: Deferred Tax Assets, in Process Research and Development $78.34M.
- 2024-12-31: Deferred Tax Assets, in Process Research and Development $79.03M.
- 2023-12-31: Deferred Tax Assets, in Process Research and Development $79.02M.
- 2022-12-31: Deferred Tax Assets, in Process Research and Development $73.28M.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2025-12-31 | $78.34M 10-K · filed 2026-03-19 |
| 2024-12-31 | $79.03M 10-K · filed 2026-03-19 |
| 2023-12-31 | $79.02M 10-K · filed 2025-03-26 |
| 2022-12-31 | $73.28M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |